Spots Global Cancer Trial Database for amivantamab
Every month we try and update this database with for amivantamab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer | NCT02609776 | Non-Small-Cell ... | Amivantamab Amivantamab Lazertinib Carboplatin Pemetrexed | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer | NCT05379595 | Advanced or Met... | Amivantamab Fluorouracil Leucovorin Oxaliplatin Irinotecan | 18 Years - | Janssen Research & Development, LLC | |
| A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations | NCT05801029 | Non-Small Cell ... | Osimertinib Amivantamab | 18 Years - 130 Years | AstraZeneca | |
| A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations | NCT05801029 | Non-Small Cell ... | Osimertinib Amivantamab | 18 Years - 130 Years | AstraZeneca | |
| A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer | NCT04945733 | Stomach Neoplas... Esophageal Neop... | Amivantamab | 20 Years - | Janssen Pharmaceutical K.K. | |
| Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib | NCT06120140 | Carcinoma, Non-... | Amivantamab Lazertinib Doxycycline Minocycline Clindamycin Chlorhexidine Noncomedogenic ... | 18 Years - | Janssen Research & Development, LLC | |
| Amivantamab in Adenoid Cystic Carcinoma | NCT05074940 | Salivary Gland ... | Amivantamab | 18 Years - | University of Cincinnati | |
| A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies | NCT04606381 | Advanced Solid ... | Ami-LC-MD Ami-LC Ami-HC Ami-HC-CF Lazertinib | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies | NCT04606381 | Advanced Solid ... | Ami-LC-MD Ami-LC Ami-HC Ami-HC-CF Lazertinib | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma | NCT05653427 | Carcinoma, Hepa... | Amivantamab | 18 Years - | Janssen Research & Development, LLC | |
| Premedication to Reduce Amivantamab Associated Infusion Related Reactions | NCT05663866 | Carcinoma, Non-... | Dexamethasone Montelukast Methotrexate Amivantamab Lazertinib | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer | NCT05379595 | Advanced or Met... | Amivantamab Fluorouracil Leucovorin Oxaliplatin Irinotecan | 18 Years - | Janssen Research & Development, LLC | |
| PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer | NCT06083857 | Non-small Cell ... | Amivantamab Tepotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Amivantamab in Adenoid Cystic Carcinoma | NCT05074940 | Salivary Gland ... | Amivantamab | 18 Years - | University of Cincinnati | |
| A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) | NCT03767075 | Advanced Solid ... | Atezolizumab Futibatinib Amivantamab | 18 Years - | Vall d'Hebron Institute of Oncology | |
| A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer | NCT04945733 | Stomach Neoplas... Esophageal Neop... | Amivantamab | 20 Years - | Janssen Pharmaceutical K.K. | |
| A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies | NCT04606381 | Advanced Solid ... | Ami-LC-MD Ami-LC Ami-HC Ami-HC-CF Lazertinib | 18 Years - | Janssen Research & Development, LLC | |
| Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations | NCT05299125 | Metastatic Non-... | Amivantamab Lazertinib Pemetrexed 500 ... | 18 Years - | Latin American Cooperative Oncology Group | |
| Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations | NCT05299125 | Metastatic Non-... | Amivantamab Lazertinib Pemetrexed 500 ... | 18 Years - | Latin American Cooperative Oncology Group | |
| A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer | NCT05498428 | Carcinoma, Non-... | Amivantamab Lazertinib Carboplatin Pemetrexed Direct Oral Ant... Low Molecular W... | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies | NCT04606381 | Advanced Solid ... | Ami-LC-MD Ami-LC Ami-HC Ami-HC-CF Lazertinib | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) | NCT04965090 | Metastatic Non ... Recurrent Non S... | Amivantamab Lazertinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) | NCT06116682 | Lung Non-Small ... | Amivantamab Biospecimen Col... Computed Tomogr... Magnetic Resona... | 18 Years - | SWOG Cancer Research Network | |
| A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | NCT04487080 | Carcinoma, Non-... | Amivantamab Osimertinib Lazertinib Placebo | 18 Years - | Janssen Research & Development, LLC | |
| Amivantamab in Adenoid Cystic Carcinoma | NCT05074940 | Salivary Gland ... | Amivantamab | 18 Years - | University of Cincinnati | |
| A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) | NCT03767075 | Advanced Solid ... | Atezolizumab Futibatinib Amivantamab | 18 Years - | Vall d'Hebron Institute of Oncology | |
| Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib | NCT06120140 | Carcinoma, Non-... | Amivantamab Lazertinib Doxycycline Minocycline Clindamycin Chlorhexidine Noncomedogenic ... | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma | NCT05653427 | Carcinoma, Hepa... | Amivantamab | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Amivantamab in People With Esophagogastric Cancer | NCT05117931 | Esophagogastric... | Amivantamab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer | NCT06083857 | Non-small Cell ... | Amivantamab Tepotinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) | NCT04965090 | Metastatic Non ... Recurrent Non S... | Amivantamab Lazertinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI | NCT05601973 | Non Small Cell ... | Amivantamab Lazertinib Zirabev | 18 Years - | ETOP IBCSG Partners Foundation | |
| A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | NCT04487080 | Carcinoma, Non-... | Amivantamab Osimertinib Lazertinib Placebo | 18 Years - | Janssen Research & Development, LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
